Display options
Cite
Zeitouni M, Sabouret P, Kerneis M, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):324-333doi: 10.1093/ehjcvp/pvaa077.
Zeitouni, M., Sabouret, P., Kerneis, M., Silvain, J., Collet, J. P., Bruckert, E., & Montalescot, G. (2021). 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. European heart journal. Cardiovascular pharmacotherapy, 7(4), 324-333. https://doi.org/10.1093/ehjcvp/pvaa077
Zeitouni, Michel, et al. "2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations." European heart journal. Cardiovascular pharmacotherapy vol. 7,4 (2021): 324-333. doi: https://doi.org/10.1093/ehjcvp/pvaa077
Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, Montalescot G. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):324-333. doi: 10.1093/ehjcvp/pvaa077. PMID: 32652000.
Copy Download .nbib Format: NLM
Share it on

Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):324-333. doi: 10.1093/ehjcvp/pvaa077.

2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations.

European heart journal. Cardiovascular pharmacotherapy

Michel Zeitouni, Pierre Sabouret, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Eric Bruckert, Gilles Montalescot

Affiliations

  1. Department of Cardiology, Institut de cardiologie (AP-HP), Sorbonne Université, ACTION Study Group, INSERM UMRS_1166, 47-83 bld de l'Hôpital, 75013 Paris, France.
  2. Department of Endocrinology, Pitié-Salpêtrière Hospital and Sorbonne University, Cardio Metabolic Institute, 83 bld de l'Hôpital, 75013 Paris, France.

PMID: 32652000 DOI: 10.1093/ehjcvp/pvaa077

Abstract

In 2019, the European Society of Cardiology and European Atherosclerosis Society released a new guideline document with substantial changes regarding the assessment of cardiovascular risk and treatments. The update of high-risk criteria and categories led to a better detection and primary prevention of patients at risk of a first cardiovascular event. Nonetheless, additional efforts are needed for a better inclusion of risk modifiers, especially specific to women, to improve risk stratification and direct primary prevention. Eventually, we discuss how these new guidelines implement PCSK9 inhibitors for very high-risk individuals and the evidence supporting new low-density lipoprotein cholesterol goals below, such as 55 and 40 mg/dL.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: [email protected].

Keywords: Guidelines; PCSSK9 inhibitors; Statins;  Dyslipidaemia

Publication Types